A different mechanism enabling survival of both melanoma and NSCLC cells in the presence of targeted therapy involves upregulation of the RTK AXL and the subsequent induction of an epithelial-to-mesenchymal transition (EMT) [38,39]. This evidence concerns the gene AXL and melanoma.